# Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia

> **NCT04275388** · — · UNKNOWN · sponsor: **Jiangxi Qingfeng Pharmaceutical Co. Ltd.** · enrollment: 426 (estimated)

## Conditions studied

- 2019 Novel Coronavirus Pneumonia

## Interventions

- **DRUG:** Xiyanping injection
- **DRUG:** Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride

## Key facts

- **NCT ID:** NCT04275388
- **Lead sponsor:** Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-15
- **Primary completion:** 2020-07-14
- **Final completion:** 2021-12-14
- **Target enrollment:** 426 (ESTIMATED)
- **Last updated:** 2020-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04275388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04275388, "Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04275388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*